Final Results from the ENESTxtnd Study of Dose-Optimized Nilotinib in Newly Diagnosed CML


Final Results from the ENESTxtnd Study of Dose-Optimized Nilotinib in Newly Diagnosed CML
Slides from a presentation at ASH 2015

Hughes TP et al. Dose-optimized nilotinib (NIL) in patients (Pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Final results from ENESTxtnd study. Proc ASH 2015;Abstract 344.